Posted on: 19th April 2018
CALGARY, AB – April 19, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease (“PKD”) and rare diseases such as autosomal dominant polycystic kidney disease (“ADPKD”)...More
Posted on: 20th March 2018
CALGARY, AB – March 20, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has issued an aggregate of 2,250,000 options to purchase common shares of the Company to certain directors, officers, consultants and employees in accordance with..More
Posted on: 27th February 2018
CALGARY, AB – February 27, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide this corporate update. “With the successful close of the Company’s recent merger with APAC Resources Inc. and the fund raise associated with that..More
Posted on: 24th February 2018
CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dave Matthews as Chief Financial Officer (“CFO”). Dave Matthews brings over 25 years of life sciences experience to XORTX...More
Posted on: 16th February 2018
CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the appointment of Allan Williams and Paul Van Damme as directors of the Company and the resignation of Dr. Alan Moore as director. Dr. Alan..More
Posted on: 16th February 2018
Vancouver, BC – January 10, 2018 – APAC Resources Inc. (“APAC“) (CSE:APG:CNX) and XORTX Pharma Corp. (“XORTX”) are pleased to announce the completion of the previously announced reverse take-over and acquisition by APAC of all of the issued and outstanding shares (“XORTX Shares”) of XORTX (the “Acquisition”). The resulting company, XORTX Therapeutics Inc. (“XRX” or..More
Posted on: 16th February 2018
Vancouver, BC – August 8, 2017 – APAC Resources Inc. (“APAC“) (CSE:APG:CNX) announced today that it has entered into a binding support agreement dated August 8, 2017 (the “Support Agreement”) with XORTX Pharma Corp. (“XORTX“) in respect of APAC’s proposed acquisition of all of the issued and outstanding shares of XORTX (“XORTX Shares”), an early..More
Posted on: 16th February 2018
Vancouver, BC – June 14, 2017 – APAC Resources Inc. (“APAC”) (CSE:APG:CNX) announced today that it has entered into a non-binding letter of intent (“Letter of Intent“) with XORTX Pharma Corp. (“XORTX“), an early development stage life science company to complete a reverse take-over transaction with the shareholders of XORTX (the “Proposed Transaction“). XORTX is..More